Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists

Details for Australian Patent Application No. 2005214378 (hide)

Owner AstraZeneca AB NPS Pharmaceuticals, Inc.

Inventors Wensbo, David; Holm, Bjorn; Kers, Annika; Staaf, Karin; Isaac, Methvin; Slassi, Abdelmalik; Xin, Tao; Arora, Jalaj; Stefanac, Tomislav; Edwards, Louise

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005214378

PCT Pub. Number WO2005/080386

Priority 60/545,292 18.02.04 US

Filing date 17 February 2005

Wipo publication date 1 September 2005

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

31 August 2006 PCT application entered the National Phase

  PCT publication WO2005/080386 Priority application(s): WO2005/080386

13 December 2007 Assignment before Grant

  AstraZeneca AB; NPS Pharmaceuticals, Inc. The application has been assigned to AstraZeneca AB

13 September 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005214379-Tetrazole compounds and their use as metabotropic glutamate receptor antagonits

2005214376-Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists